Korro Bio Inc.

About Korro Bio Inc.

Korro Bio is focused on delivering the promise of genetic medicines to complex prevalent diseases by editing a single letter on RNA to modulate biological pathways. Their mission is to rewrite the future through innovative RNA editing technologies.

Products & Services

Genetic Medicines:Precision medicines using RNA editing to address rare and prevalent diseases, including repairing proteins caused by genetic mutations or altering proteins to activate biological pathways.

KRRO-110:A drug candidate for Alpha-1 Antitrypsin Deficiency (AATD), aimed at providing clinical benefits for liver and lung manifestations.

OPERA Platform:A proprietary platform called Oligonucleotide Promoted Editing of RNA (OPERA®) that enables the discovery and development of RNA editing drug candidates.

Specialties

RNA Editing Genetic Medicines Alpha-1 Antitrypsin Deficiency (AATD) Treatment Precision Medicine

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Private Placement (PIPE) T: - FT: Private Placement (PIPE)	A: 70000000 MR: - FA: approximately $70.0 million FAN: 70000000	D: 2024-04-18 FD: 2024-04-18	7 investors

Private Placement (PIPE) Latest

2024-04-18

$70.0M

7 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

R

Ram Aiyar

Chief Executive Officer and President

L

Loic Vincent

Chief Scientific Officer

M

Monica Goldklang

Assistant Professor of Medicine in Anesthesiology and Director, Alpha-1 Foundation Clinical Resource Center, Columbia University New York, USA

N

Noel G. McElvaney

Professor of Medicine at the Royal College of Surgeons in Ireland, Head of the Irish Centre for Genetic Lung Disease, Beaumont Hospital, Dublin, Ireland, and Founder of the Alpha-1 Foundation of Ireland

P

Pavel Strnad

Professor of Translational Gastroenterology and Senior Physician at the University Hospital Aachen, Department of Medicine III, Aachen, Germany

J

Jeffrey Teckman

Professor of Pediatrics, Biochemistry and Molecular Biology

View 18 more team members with Pro

Unlock Full Team Directory

Recent News

Korro Bio Inc. Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised